[Asia Economy Reporter Lee Gwan-ju] Engchem Life Sciences announced on the 12th that it will attend the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO), held in Toronto from June 23 to 25 (local time), to present the results of its Phase 2 clinical trial on oral mucositis.
At this conference, the company plans to present the results of a U.S. Phase 2 clinical trial confirming the safety, tolerability, and efficacy of 'EC-18' for chemotherapy- and radiotherapy-induced oral mucositis (CRIOM) in patients with head and neck cancer.
According to the final report of the U.S. Phase 2 clinical trial for the oral mucositis treatment previously announced by Engchem Life Sciences, the primary endpoint, duration of severe oral mucositis, was reduced by 100%, with a median of 0 days in the treatment group compared to 13.5 days in the placebo group. The secondary endpoint, incidence rate of severe oral mucositis, decreased by 37.1%.
An Engchem Life Sciences official said, "We are pleased to present excellent clinical results at MASCC and ISOO. We expect that the presentation of clinical results at this annual conference will further accelerate licensing-out opportunities."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
